Key statistics
On Thursday, Immuneering Corp (IMRX:NMQ) closed at 4.96, 350.91% above the 52 week low of 1.10 set on May 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.04 |
|---|---|
| High | 5.15 |
| Low | 4.90 |
| Bid | 4.80 |
| Offer | 5.10 |
| Previous close | 5.05 |
| Average volume | 1.02m |
|---|---|
| Shares outstanding | 64.57m |
| Free float | 53.04m |
| P/E (TTM) | -- |
| Market cap | 326.08m USD |
| EPS (TTM) | -1.78 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
- Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
- Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
- Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
- Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
- Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
- Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
- Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
- Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
More ▼
